文献速递乳腺癌支持与姑息治疗

早期与转移性乳腺癌EORTC QLQ-C30参考值

Reference values for the EORTC QLQ-C30 in early and metastatic breast cancer.
PubMed 文献 · Eur J Cancer · 2019-12-12

研究基于三项EORTC随机对照试验(n=4115)和三项PDS随机对照试验(n=1406),计算并按疾病分期、年龄、体能状态、合并症和地区分层的EORTC QLQ-C30参考值。早期乳腺癌患者基线功能评分高、症状 prevalence 低,转移性乳腺癌患者功能评分低、症状 prevalence 高;转移性乳腺癌中体能状态差和合并症与更差基线HRQoL相关。年龄和国家未见一致差异。

要点

  • 早期乳腺癌基线HRQoL较好,功能评分高且症状少。
  • 转移性乳腺癌基线HRQoL较差,功能评分低且症状多。
  • 转移性乳腺癌中体能状态差和合并症提示更差基线HRQoL。

核心结论

  • EORTC QLQ-C30参考值在乳腺癌不同分期、体能状态和合并症间存在差异,且得到独立数据集支持。

研究设计与样本

  • 研究检索EORTC(主数据集)和Project Data Sphere(PDS,比较数据集)中采用QLQ-C30评估基线HRQoL的乳腺癌随机对照试验。
  • 纳入三项EORTC随机对照试验(n=4115)和三项PDS随机对照试验(n=1406),按疾病分期、年龄及可获得的体能状态、合并症和地区分层计算参考值。

主要发现

  • 早期乳腺癌患者基线功能评分高且症状 prevalence 低,转移性乳腺癌患者功能评分低且症状 prevalence 高。
  • 转移性乳腺癌中,体能状态差和存在合并症反映更差的基线HRQoL。
  • 年龄和国家间未发现一致差异。

临床怎么用

  • 这些参考值有助于临床解读乳腺癌患者EORTC QLQ-C30评分,并可支持随机对照试验设计和医疗干预比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Considering the worldwide incidence of breast cancer (BC) and the importance of health-related quality of life (HRQoL) assessment, there is a growing need to have accurate and up-to-date reference values (RVs). RVs are useful for the design of randomised controlled trials (RCTs) and as benchmarks for comparison of cancer RCTs and health care interventions. This study aimed to provide RVs for the QLQ-C30 in early BC (EBC) and metastatic BC (MBC). General patterns of main results from the EORTC dataset (main dataset) were compared with the PDS dataset (comparison dataset) to see whether they would be consistent across pre-defined covariates. METHODS: European Organization for Research and Treatment of Cancer (EORTC) (main dataset) and Project Data Sphere (PDS) (comparison dataset) were searched to identify BC RCTs where baseline HRQoL (before treatment) was assessed with the QLQ-C30. RVs were calculated and stratified by disease stage, age, and when available, performance status (PS), comorbidity and region. RVs were reported using descriptive statistics. RESULTS: Data from three EORTC (n = 4115) and three PDS RCTs (n = 1406) were included in the analysis. While EBC patients presented better HRQoL with high baseline functioning scores and low prevalence of symptoms, MBC patients reported worse HRQoL with lower functioning scores and more prevalence of symptoms. In MBC, poor PS and presence of comorbidities reflected worse baseline HRQoL. No consistent differences were found for age and countries. CONCLUSION: These up-to-date RVs for the EORTC QLQ-C30 in BC show differences in HRQoL scores between stages, PS, and comorbidities. These findings, supported by an independent dataset, will help the clinical interpretation of scores for BCpatients.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Mierzynska J, Taye M, Pe M, et al. Reference values for the EORTC QLQ-C30 in early and metastatic breast cancer. Eur J Cancer. 2019. PMID: 31838407. doi:10.1016/j.ejca.2019.10.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。